🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

20 results for “Astellas Pharma Inc” Clear

  1. ASP8825

    Astellas Pharma Inc

    Restless Legs Syndrome

    phase 3 small molecule completed

    1 trial

  2. Fezolinetant

    Astellas Pharma Inc

    Hot Flashes

    phase 3 small molecule completed

    1 trial

  3. Isavuconazole

    Astellas Pharma Inc

    Candidiasis, Invasive

    phase 3 small molecule completed

    1 trial

  4. Mirabegron

    Astellas Pharma Inc

    Overactive Bladder (OAB)

    phase 3 small molecule terminated

    1 trial

  5. Ramosetron

    Astellas Pharma Inc

    Vomiting

    phase 3 small molecule completed

    1 trial

  6. Tacrolimus capsule

    Astellas Pharma Inc

    Myasthenia Gravis

    phase 3 small molecule completed

    1 trial

  7. YM060

    Astellas Pharma Inc

    Diarrhea-predominant Irritable Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  8. gilteritinib

    Astellas Pharma Inc

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule completed

    1 trial

  9. linaclotide

    Astellas Pharma Inc

    Chronic Constipation

    phase 3 small molecule completed

    1 trial

  10. tacrolimus

    Astellas Pharma Inc

    Kidney Transplantation

    phase 3 small molecule completed

    1 trial

  11. ASP5094

    Astellas Pharma Inc

    Rheumatoid Arthritis (RA)

    phase 2 small molecule completed

    1 trial

  12. ASP8273

    Astellas Pharma Inc

    Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  13. Gilteritinib

    Astellas Pharma Inc

    Non-Small-Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  14. Tacrolimus

    Astellas Pharma Inc

    Bone Marrow Transplantation

    phase 2 small molecule completed

    1 trial

  15. YM150

    Astellas Pharma Inc

    Thromboembolism

    phase 2 small molecule completed

    1 trial

  16. ASP1941

    Astellas Pharma Inc

    Healthy

    phase 1 small molecule completed

    1 trial

  17. ESN364

    Astellas Pharma Inc

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  18. TRK-100STP (BERASUS LA)

    Astellas Pharma Inc

    Healthy

    phase 1 small molecule completed

    1 trial

  19. ADVAGRAF

    Astellas Pharma Inc

    Renal Transplantation

    approved small molecule completed

    1 trial

  20. Ramosetron

    Astellas Pharma Inc

    Irritable Bowel Syndrome

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources